BioStock: High expectations on a deal for Respiratorius

In June, Respiratorius raised just over SEK 25 million in a heavily oversubscribed rights issue. The capital will, among other things, be allocated to finance remaining preparations for a phase III study with cancer candidate VAL001. As the study looms, expectations of a partnership agreement intensify. Speculation increased even further after the company received the recommendation from the European Medicines Agency to go directly to Phase III without conducting a Phase IIb study.

Read the full article at biostock.se:

https://www.biostock.se/en/high-expectations-on-a-deal-for-respiratorius/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se